Autologous hematopoietic stem cell transplantation for very active relapsing-remitting multiple sclerosis: report of two cases.
Autologous hematopoietic stem cell transplantation (AHSCT) has been proposed as a rescue treatment in multiple sclerosis (MS) patients not responding to first- or second-line therapies. To date, most of the treated cases had a secondary progressive disease course. However, patients with high inflammatory activity, but no secondary progression of the disease, could be candidates to take greater advantage of AHSCT. In this paper, we report two cases with very active, relapsing-remitting (RR) MS, who underwent AHSCT, and obtained a dramatic resolution to disease activity.
Portaccio
E
E
Department of Neurology, University of Florence, and Bone Marrow Transplantation Unit, Careggi Hospital, Florence, Italy. portilio@tin.it
Amato
M P
MP
Siracusa
G
G
Pagliai
F
F
Sorbi
S
S
Guidi
S
S
Bosi
A
A
Saccardi
R
R
D000328:Adult; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000628:therapy*; D012074:Remission Induction; D014182:Transplantation, Autologous